Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Statin prescription in men and women at cardiovascular risk: to whom and when?
Jasper J. Brugts,Jaap W. Deckers +1 more
TL;DR: The use of statins in low-risk patients without CVD remains a matter of intense debate, even following the latest findings from the JUPITER, and the overall absolute risk reductions and cost-effectiveness of long-term statin prescription should be kept in mind.
Journal ArticleDOI
Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women.
Cathleen M Rivera,Juhee Song,Laurel A. Copeland,Chris Buirge,Marcia G. Ory,Catherine J. McNeal +5 more
TL;DR: The majority of women for whom aspirin is recommended for primary and secondary prevention of CVD were not following national guidelines, and the main factors that favored aspirin use were a family history ofCVD or high cholesterol.
Journal ArticleDOI
Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2).
Bruce M Biccard,Alben Sigamani,Matthew T. V. Chan,Daniel I. Sessler,Andrea Kurz,Jacques G. Tittley,Theodore Rapanos,John Harlock,David Szalay,Maria Tiboni,Ekaterine Popova,Skarlet Marcell Vásquez,Barbara Kabon,Mohammed Amir,Marko Mrkobrada,Bhupendra Mehra,H. El Beheiry,E. Mata,B. Tena,S. Sabaté,M. K. Zainal Abidin,V. R. Shah,Kumar Balasubramanian,Philip J. Devereaux +23 more
TL;DR: The aim of this substudy was to determine whether there is a subgroup effect of initiating or continuing aspirin in patients undergoing vascular surgery.
Journal ArticleDOI
The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study.
Wen-Kuan Huang,Meng-Jiun Chiou,Kuang-Hui Yu,Yung-Chang Lin,Tsai-Sheng Yang,Jen-Shi Chen,Chia-Jung Kuo,Lai-Chu See +7 more
TL;DR: Considerable evidence suggests that aspirin has a chemopreventive effect on colorectal cancer (CRC), however, optimal dose and treatment duration have not been defined, and data on the effects of low‐dose aspirin are contradictory.
Journal ArticleDOI
Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.
TL;DR: Based on the current totality of evidence from predominantly low risk subjects, any decision to prescribe aspirin for primary prevention should be an individual clinical judgment by the healthcare provider that weighs the absolute benefit in reducing the risk of a first MI against the absolute risk of major bleeding.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.